The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer Still Following the Right TRAIL?

Research output: Contribution to journalEditorial

Standard

The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer Still Following the Right TRAIL? / McGrath, Emmet.

In: Journal of Thoracic Oncology, Vol. 6, No. 6, 01.06.2011, p. 983-987.

Research output: Contribution to journalEditorial

Harvard

APA

Vancouver

Author

Bibtex

@article{24d4189c9ee94bf7902653341751ac13,
title = "The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer Still Following the Right TRAIL?",
abstract = "Tumor necrosis factor-related apoptosis-inducing ligand is a type II membrane-bound protein whose C-terminal extracellular domain shows clear homology to other tumor necrosis factor family members. It is constitutively expressed on macrophages, T cells, natural killer cells, and dendritic cells and selectively kills transformed cells leaving most of the normal cells alone. This selectivity has led to great interest in it use as a therapeutic agent for the treatment of malignancy. In this review, this critical pathway is described, highlighting its mechanistic manipulation for therapeutic benefit and the recent phase I and II trials in lung cancer that have been performed or are currently ongoing are also discussed.",
keywords = "Small cell lung cancer, Non-small cell lung cancer, Apoptosis, TNF-related apoptosis-inducing ligand (TRAIL), Clinical trials",
author = "Emmet McGrath",
year = "2011",
month = jun,
day = "1",
doi = "10.1097/JTO.0b013e318217b6c8",
language = "English",
volume = "6",
pages = "983--987",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

RIS

TY - JOUR

T1 - The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer Still Following the Right TRAIL?

AU - McGrath, Emmet

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Tumor necrosis factor-related apoptosis-inducing ligand is a type II membrane-bound protein whose C-terminal extracellular domain shows clear homology to other tumor necrosis factor family members. It is constitutively expressed on macrophages, T cells, natural killer cells, and dendritic cells and selectively kills transformed cells leaving most of the normal cells alone. This selectivity has led to great interest in it use as a therapeutic agent for the treatment of malignancy. In this review, this critical pathway is described, highlighting its mechanistic manipulation for therapeutic benefit and the recent phase I and II trials in lung cancer that have been performed or are currently ongoing are also discussed.

AB - Tumor necrosis factor-related apoptosis-inducing ligand is a type II membrane-bound protein whose C-terminal extracellular domain shows clear homology to other tumor necrosis factor family members. It is constitutively expressed on macrophages, T cells, natural killer cells, and dendritic cells and selectively kills transformed cells leaving most of the normal cells alone. This selectivity has led to great interest in it use as a therapeutic agent for the treatment of malignancy. In this review, this critical pathway is described, highlighting its mechanistic manipulation for therapeutic benefit and the recent phase I and II trials in lung cancer that have been performed or are currently ongoing are also discussed.

KW - Small cell lung cancer

KW - Non-small cell lung cancer

KW - Apoptosis

KW - TNF-related apoptosis-inducing ligand (TRAIL)

KW - Clinical trials

U2 - 10.1097/JTO.0b013e318217b6c8

DO - 10.1097/JTO.0b013e318217b6c8

M3 - Editorial

C2 - 21623278

VL - 6

SP - 983

EP - 987

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 6

ER -